AMAÇ: Kandidiyazis HIV ve AIDS hastalarındaki önde gelen fırsatçı mantar enfeksiyonudur. YÖNTEM: Bu enfeksiyonun Nylon Sağlık Bölgesi\'nde, farklı CD4+ T hücre kategorilerindeki prevalansını saptamak üzere 304 HIV pozitif katılımcı arasında Mart-Ağustos 2007 tarihlerinde, kesitsel bir araştırma yapıldı. Hastalar yüksek düzeyde aktif antiretroviral tedavi (Highly active antiretroviral therapy: HAART) alan ve almayan olarak iki gruba ayrıldı. Ağız, vajinal-üretral sürüntü ve idrar olmak üzere her hastadan üç örnek alındı. BULGULAR: Toplam 204 hasta (%67.1, %95GA:%61.8-%72.4), kandidiyazis için riski artırıcı özelliklere sahipti, bunlardan en fazla görülen antibiyotik tedavisi alıyor olmak (%63.7) ve hamilelik (%7.3) idi. Kandidiyazis CD4+ T hücre sayısı 200\'ün altında olanlarda (%66), olmayanlardan (%17.9) daha yaygındı (p
AIM: Candidiasis is the leading opportunistic mycosis in HIV and AIDS patients. METHOD: In order to determine its prevalence in patients with different CD4+ T cell categories in the Nylon Health District in Douala, a cross-sectional study was carried out whereby 304 HIV positive individuals were recruited between March and August, 2007. They were divided into two groups; those on highly active antiretroviral therapy (HAART) and those not on HAART. Three samples constituting mouth, vaginal/urethral swabs and urine were collected from each subject. RESULTS: A total of 204 (67.1%) [95% confidence interval (CI): 0.618-0.724] of these patients had more than one predisposing condition to candidiasis, with those on antibiotic therapy having the highest prevalence (63.7%) followed by pregnant patients (7.3%) (P < 0.05). Candidiasis was more common in patients with low CD4+ T cell count (<200) [66%] than patients with higher CD4+ T cell count (17.9% ) (P<0.05). One hundred and sixty one (53%) of the patients had candidiasis whereby those not on HAART were more frequently infected (69.6%) than those on HAART (30.1%) (p< 0.05). CONCLUSION: We conclude that candidiasis is a major opportunistic infection in HIV patients and should be checked especially in patients not yet on antiretroviral therapy.
1. Neil K. V. Multicenter evaluation of a macrobroth antifungal susceptibility test for yeasts. Antimicrob Agents. 1993; 304: 359- 365.
2. Hidalgo DL, Roberts GD, Galgiani JE, et al. Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin. BJ Clin Microbiol. 2006; 23: 298-301.
3. Ministère de la Santé Publique. Plan stratégie national de lutte contre le VIH/SIDA. Comité National de Lutte Contre le SIDA, Cameroun. 2006-2010, Yaoundé, Cameroun, 2009.
4. Sub-Saharan Africa HIV/AIDS statistics. Available at: www.avert.org/africa-hiv-aidsstatistics- htm. [Accessed Date: 23.10.2010].
5. Cheesbrough, M. District Laboratory Practice in Tropical Countries Part 2. Cambridge low price Edition, Cambridge University Press, London. 2000, p. 243-244.
6. Isibor JO, Eghubare AE, Omoregie R. Germ tube formation in Candida albicans: evaluation of human and animal sera and inoculation atmosphere. SEMJ. 2005; 6 (1,2): 1-9.
7. Guy BS, Ernst D, Goncalves J. Clinical data based optimal STI strategies for HIV: a reinforcement learning approach. Department of Engineering (Control group). University of Cambridge, United Kingdom. 2006, p. 5-15.
8. Cambi A, Gijzen K, De Vries JM, et al. The Ctype lectin DC-SIGN (CD209) is an antigen – uptake receptor for Candida albicans on dentritic cells. Eur J Immunol. 2003; 33(2): 532-538.
9. Prabhala, RH and Wira CR. Influence of estrus cycle and estradiol on mitogenic responses of splenic T and B lymphocytes. Adv Exp Med. Biol. 1995; 371A: 379-381.
10. Saavedra M, Taylor B, Lukas N, Fidel PL. Local production of chemokines during experimental vaginal candidiasis. Infect Immun. 1999; 67(11): 5820-5829.
11. Romani, L, Bistoni F, Puccetti P. Adaptation of Candida albicans to the host environment: the role of morphogenesis I virulence and survival in mammalian hosts. Curr Opin Microbiol. 2003; 6(4): 338-343.
12. Giorgio S, Maria B, Daniela A, et al. Immune Cell-Mediated Protection against Vaginal Candidiasis: Evidence for a Major Role of Vaginal CD4-T Cells and Possible Participation of Other Local Lymphocyte Effectors. Infect Immun. 2002, p. 791-797.
13. Gomez, MJ, Torosantucci A, Arancia S, Maras B, Parisi L, and Cassone A. Purification and biochemical characterization of a 65-kilodalton mannoprotein (MP65), a main target of anti-Candida cell-mediated immune responses in humans. Infect Immun. 1996; 64(7): 2577-2584.
14. Tacconelli E, De Bernardis F, Tumbarello M, Torosantucci A, Cauda R. A direct effect of HIV protease inhibitors on Candida albicans: prevention of oral candidiasis through inhibition of fungal proteinase. Abstract, 6th Conference, Retroviral Opportunistic Infection .Chicago Illinois. 1999; 6: 209.
15. De Bernardis, F, Sullivan FPA, Cassone A. Aspartyl proteinases of Candida albicans and their role in pathogenicity: Med Mycol. 2001; 39(4): 303-313.
16. Cassone A, De Bernardis F, Torosantucci A, Tacconelli E, Tumbarello M, Cauda R. In Vitro and In Vivo Anticandidal Activity of Human Immunodeficiency Virus Protease Inhibitors. J Infect Dis. 1999; 180(2): 448- 453.